Type 2 Diabetes

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

An expert cardiologist and endocrinologist explain the factors considered when creating a treatment plan for type 2 diabetes.

Jennifer B. Green, MD, and Dennis Bruemmer, MD, PhD, discuss the increasing prevalence of type 2 diabetes around the world, and the populations facing higher risk.

A recent study published in JAMA Network Open describes the impact of the COVID-19 pandemic and related issues on access to insulin among patients with diabetes in the United States.

Data presented at ASN Kidney Week 2021 suggests dapagliflozin use was associated with a reduction in the rate of kidney function decline in patients with chronic kidney disease, regardless of whether they have diabetes.

Results of FIDELITY suggest use of finerenone was associated with reductions in risk of all nonfatal kidney end points included in the analysis, regardless of CKD severity.

An analysis of FIGARO-DKD from Kidney Week 2021 suggests finerenone use was associated with reductions in risk of multiple renal end points, including a 36% reduction in the need for dialysis.

Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.

Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.

An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.

George Bakris, MD, takes part in a Q&A with Endocrinology Network staff to explore the design of the upcoming FIND-CKD trial and potential research priorities surrounding finerenone moving forward.

Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.

A significant decrease of -55.3 insulin fills per week during the pandemic was observed, in comparison to before the pandemic.

Data presented at ACR Convergence 2021 suggest statin initiation was associated with a 32% reduction in risk of cardiovascular disease, 54% reduction in risk of all-cause mortality, and a 33% increase in risk of type 2 diabetes.

An analysis of data from more than 160k adults with type 2 diabetes in Scotland provides insight into the incidence of diabetes remission and factors associated with increased likelihood of achieving remission.

A time-conditional propensity score-matched analysis suggests statin initiation was associated with reductions in risk of cardiovascular disease and all-cause mortality but an increase in the risk of new diabetes in patients with rheumatoid arthritis.

Sulfonylurea and/or insulin deintensification occurred in fewer than 50% of older adults with diabetes within 100 days of a hypoglycemia-associated ED visit.

Our latest endocrine case report features a man in his mid-60’s with a history of diabetes and obesity presenting with left groin pain followed by a syncopal episode. Check out the CT scan and determine the correct diagnosis.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Data show In youth with obesity, but not healthy weight, visceral fat was positively associated with PWV and was predictive of PWV beyond BMI and waist circumference.

In older patients receiving medication intensification, no differences were seen in the risk of severe hyperglycemia, severe hypoglycemia, or death at 1 year.

A case study for a patient who required additional SGLT-2 inhibitors to help reduce progression of renal disease is presented, and Drs Robert Busch, Dhiren Patel, and Muthiah Vadugananthan share their final thoughts on renal protective agents.

Robert Busch, MD, and Muthiah Vadugananthan, MD, MPH, share their thoughts on the multifunctional responsibility of managing a patient’s renal disease.

Dr Robert Busch and Dr Muthiah Vadugananthan provide insights on educating their peers on the importance of decreasing renal progression.

An expert endocrinologist and cardiologist discuss the risks and complications of renal disease associated with diabetes and cardiovascular disease. Dr Robert Busch also provides an overview of some of the studies done in renal impairment.